SV

Street Verdict

Analyst Scorecard

A record of what Vishal Manchanda said publicly, with the source. Not advice.

Pending — not yet graded
“Neutral on the broader Pharma sector for FY27, anticipating a difficult period due to potential weakness in the US business for larger names like Sun, Cipla, and Reddy’s, which could dent margins. However, he expects the Indian business to maintain a secular growth trajectory of 9% and other emerging markets to grow 8-11%.”
Nifty PharmaNeutralCalled 14 Feb 2025
Verdict:PENDING

This call has no verdict yet — it is graded HIT or MISS against real price data once a close decides it. Save it above to find it again from your profile.

Read the original articleSee Vishal Manchanda’s full track record